Exelixis Inc Investor Briefing to Discuss Data Presented at ESMO 2020 Transcript
Thanks for joining us, ladies and gentlemen. Please welcome, Susan Hubbard.
Hello, everyone, and welcome to the Exelixis Investor Briefing at the ESMO Virtual Congress 2020. I'm Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations for Exelixis.
We are very pleased to have you join us for a review of the CheckMate 9ER trial results, which were just presented a few hours ago in ESMO's presidential symposium session by the principal investigator for the study, Dr. Toni Choueiri of the Dana-Farber Cancer Institute. We have a very prestigious panel of physicians joining Dr. Choueiri today to discuss the results from CheckMate 9ER as well as data from 2 renal cell carcinoma cohorts of COSMIC-021 also being presented at the Congress. Following our panel discussion, we'll have a question-and-answer session where we'll field questions from the audience, which I've already received, so thank you, everybody, for sending your questions in.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |